2 weeks Ago By ABMN Staff
HBK Sorce Advisory LLC purchased a new position in shares of Regeneron Pharmaceuticals, Inc. ( NASDAQ:REGN – Free Report ) in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 194 shares of the biopharmaceutical company’s stock, valued at approximately $204,000.
Several other large investors have also recently added to or reduced their stakes in REGN. West Paces Advisors Inc. raised its holdings in shares of Regeneron Pharmaceuticals by 575.
0% during the 1st quarter. West Paces Advisors Inc. now owns 27 shares of the biopharmaceutical company’s stock valued at $26,000 after buying an additional 23 shares during the period.
Stephens Consulting LLC acquired a new stake in Regeneron Pharmaceuticals in the second quarter valued at approximately $26,000. Sachetta LLC raised its stake in shares of Regeneron Pharmaceuticals by 71.4% during the second quarter.
Sachetta LLC now owns 24 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 10 shares during the period. Crewe Advisors LLC acquired a new position in shares of Regeneron Pharmaceuticals during the first quarter worth $28,000. Finally, Lynx Investment Advisory purchased a new position in shares of Regeneron Pharmaceuticals in the second quarter valued at $33,000.
83.31% of the stock is currently owned by institutional investors and hedge funds. Insider Activity In related news, EVP Marion Mccourt sold 1,137 shares of the firm’s stock in a transaction that occurred on Monday, July 1st.
The stock was sold at an average price of $1,047.11, for a total value of $1,190,564.07.
Following the sale, the executive vice president now directly owns 12,931 shares in the company, valued at approximately $13,540,179.41. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink .
In related news, EVP Marion Mccourt sold 1,137 shares of the stock in a transaction dated Monday, July 1st. The shares were sold at an average price of $1,047.11, for a total value of $1,190,564.
07. Following the completion of the transaction, the executive vice president now owns 12,931 shares in the company, valued at approximately $13,540,179.41.
The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link . Also, CFO Christopher R. Fenimore sold 5,680 shares of the business’s stock in a transaction dated Wednesday, August 28th.
The stock was sold at an average price of $1,205.33, for a total transaction of $6,846,274.40.
Following the sale, the chief financial officer now owns 15,305 shares in the company, valued at $18,447,575.65. The disclosure for this sale can be found here .
Over the last 90 days, insiders have sold 10,026 shares of company stock valued at $11,498,705. Insiders own 7.48% of the company’s stock.
Wall Street Analysts Forecast Growth View Our Latest Analysis on Regeneron Pharmaceuticals Regeneron Pharmaceuticals Price Performance Shares of NASDAQ REGN opened at $1,153.35 on Monday. The company has a debt-to-equity ratio of 0.
10, a current ratio of 5.44 and a quick ratio of 4.62.
The firm has a market capitalization of $127.15 billion, a PE ratio of 34.07, a P/E/G ratio of 3.
97 and a beta of 0.12. Regeneron Pharmaceuticals, Inc.
has a 1-year low of $769.19 and a 1-year high of $1,211.20.
The business’s fifty day moving average price is $1,124.22 and its two-hundred day moving average price is $1,026.46.
Regeneron Pharmaceuticals ( NASDAQ:REGN – Get Free Report ) last released its quarterly earnings data on Thursday, August 1st. The biopharmaceutical company reported $11.56 earnings per share for the quarter, topping analysts’ consensus estimates of $8.
93 by $2.63. Regeneron Pharmaceuticals had a net margin of 32.
04% and a return on equity of 16.80%. The business had revenue of $3.
55 billion for the quarter, compared to analysts’ expectations of $3.38 billion. During the same quarter last year, the company earned $8.
79 EPS. The company’s revenue for the quarter was up 12.3% compared to the same quarter last year.
On average, research analysts expect that Regeneron Pharmaceuticals, Inc. will post 37.8 EPS for the current year.
Regeneron Pharmaceuticals Company Profile ( Free Report ) Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. Featured Stories Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.
com's FREE daily email newsletter ..
